Advances in Surgery and (Neo) Adjuvant Therapy in the Management of Pancreatic Cancer
- PMID: 38429197
- DOI: 10.1016/j.hoc.2024.01.004
Advances in Surgery and (Neo) Adjuvant Therapy in the Management of Pancreatic Cancer
Abstract
A multimodality approach, which usually includes chemotherapy, surgery, and/or radiotherapy, is optimal for patients with localized pancreatic cancer. The timing and sequence of these interventions depend on anatomic resectability and the biological suitability of the tumor and the patient. Tumors with vascular involvement (ie, borderline resectable/locally advanced) require surgical reassessments after therapy and participation of surgeons familiar with advanced techniques. When indicated, venous reconstruction should be offered as standard of care because it has acceptable morbidity. Morbidity and mortality of pancreas surgery may be mitigated when surgery is performed at high-volume centers.
Keywords: Adjuvant therapy; Borderline-resectable; Locally-advanced; Neoadjuvant therapy; Pancreatectomy; Pancreatic cancer; Resectability.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure A.C. Wei received institutional clinical trial funding from IPSEN pharmaceuticals. M. Liu has no relevant conflicts of interest to report. Memorial Sloan Kettering has institutional financial interests relative BioNTech, Epistem Prognostics, Clarity Pharmaceuticals.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical